Other languages Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-28 pm EDT			5-day change	1st Jan Change
0.6044 ^USD	-2.62%		-5.52%	-18.94%

May. 07	Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy	CI
Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy	May. 07
Traws Pharma, Inc. Announces Chief Executive Office Changes	Apr. 04
Traws Pharma, Inc. Announces Board Changes	Apr. 04
Onconova Therapeutics Shares Drop; Company to Merge With Trawsfynydd Therapeutics	Apr. 02
Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc	Apr. 02
Onconova Therapeutics, Inc. completed the acquisition of Trawsfynydd Therapeutics, Inc.	Apr. 01
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01
Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma	Dec. 12
Onconova Therapeutics? Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i?s	Dec. 08
Onconova Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer	23-10-24
Onconova Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma	23-06-14
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade	23-05-25
Onconova Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Onconova Therapeutics Doses First Patient in Clinical Trial of Endometrial Cancer Combination Therapy	23-05-11
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer	23-05-11
Top Midday Gainers	23-04-21
Onconova Therapeutics Chief Medical Officer Mark Gelder Dies Unexpectedly	23-04-06
Onconova Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Other languages

Filters